Caribou Biosciences, Inc. (CRBU) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $136M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerCaribou Biosciences, Inc. (CRBU) trades at $1.37 with MoonshotScore 15/100 (Grade F). Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies.
Price as of Sep 11, 2026 · Last analyzed: Sep 8, 2026Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies. Their lead product candidates include CB-010, CB-011, CB-012 and CB-020 for treating hematologic malignancies and solid tumors.
CRBU stock analysis for 2026: Analysts have set a consensus price target of $5.00 for Caribou Biosciences, Inc., suggesting 265.0% upside from the current price of $1.37. The AI MoonshotScore is 15/100, in the Weak band (below 45) — a research signal, not a recommendation. Key factors: analyst coverage, AI-driven quantitative scoring.
CRBU: 2/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Strongest side: Growth Durability (4/10, Weak). Weakest side: Business Quality (1/10, Negative).
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Caribou Biosciences, Inc. Company Overview
Who Are CRBU's Competitors?
CRBU is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ORMP Oramed Pharmaceuticals Inc. | $4.74 | -0.84% | $194M | — |
| ICCC ImmuCell Corporation | $9.91 | +0.05% | $89.7M | — |
| RLYB Rallybio Corporation | $16.75 | -1.30% | $88.9M | — |
| NAGE Niagen Bioscience Inc | $3.04 | -0.49% | $242M | — |
| QTTB Q32 Bio Inc. | $10.77 | -3.37% | $320M | — |
| NWPHF Newron Pharmaceuticals S.p.A. | $20.00 | 0.00% | $416M | — |
| CRMD CorMedix Inc. | $7.93 | -2.40% | $623M | — |
| MDXG MiMedx Group, Inc. | $4.60 | -1.71% | $671M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are the Key Risks for CRBU?
Financial-distress signal — its Altman Z-Score of -5.97 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
Research confidence
Broad, current evidence sits behind this analysis.
- ● Scored on 91% of our measures
- ● Price is current
- ● Latest filing 29 days ago
- ● Covered by analysts
Why 15?
Measured against companies in the same sector. The figures below are the factor contributions the scoring engine itself produced.
What is helping
- +0.19 Short-term liquidity (Financial Strength)
- +0.15 Price to book (Valuation)
- +0.13 Revenue growth (Growth)
What is holding it back
- -0.78 Gross margin (Business Quality)
- -0.78 Operating margin (Business Quality)
- -0.78 Net margin (Business Quality)
Risk penalties applied
- -1.89 Bankruptcy-risk score in the distress zone
- -2.00 Loss-making with negative retained earnings
Contribution = how far the company sits from its sector on that measure, weighted by how much the pillar counts. Not investment advice. How the score is built →
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 12 |
| 2026-08-26 | 12 |
| 2026-08-29 | 12 |
| 2026-09-01 | 14 |
| 2026-09-04 | 14 |
| 2026-09-07 | 14 |
| 2026-09-10 | 14 |
What changed?
The grade moved from 12 to 14 (+2).
What moved it up or down:
- +7 Growth
Held back by:
- -4 Financial Strength
Over the same 18 days the stock moved -13.3%.
Caribou Biosciences, Inc. Financial Trajectory
Caribou Biosciences, Inc. (CRBU) reported $1.5M in revenue for Q2 FY2026, a decline of 37.5% compared to the prior quarter. The company recorded a net loss of $24.3M, with diluted EPS of $-0.24. Revenue has contracted over three consecutive quarters, which investors in this micro-cap its sector stock should monitor closely. Across the four most recent quarters, CRBU averaged $-0.27 in diluted EPS.
How Caribou Biosciences, Inc. Is Valued
Caribou Biosciences, Inc. carries a market capitalization of $136M, placing it in the micro-cap category. Analyst price targets span from $3.00 to $7.00, with a consensus of $5.00. At the current price of $1.37, that implies approximately 265% upside potential.
Key Financial Metrics
Return on assets is -89.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -61.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.22 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -83.7%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Caribou Biosciences, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.97 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
Caribou Biosciences, Inc. has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 13.4% above estimates on average.
Insider Activity
The most recent 12 insider filings for Caribou Biosciences, Inc. break down as 5 sales and 7 purchases. On net that is roughly 966K shares acquired (about $1.5M) — insiders putting money in tends to read as conviction.
CRBU Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 FY2026 | $1M | -$24M | -$0.24 |
| Q1 FY2026 | $2M | -$25M | -$0.26 |
| Q4 FY2025 | $4M | -$26M | -$0.28 |
| Q3 FY2025 | $2M | -$28M | -$0.30 |
Q2 FY2026 · filed 13 Aug 2026 · SEC EDGAR →
Based on FMP financials and quantitative analysis
CRBU Latest News
-
BlackRock Inc. Invests $13.76 Million in Caribou Biosciences, Inc. $CRBU
defenseworld.net · Sep 4, 2026
-
Here's Why You Should Retain IQVIA Stock in Your Portfolio Now
Yahoo! Finance: CRBU News · Aug 26, 2026
-
Brokerages Set Caribou Biosciences, Inc. (NASDAQ:CRBU) Price Target at $7.75
defenseworld.net · Aug 17, 2026
-
B of A Securities Maintains Buy on Caribou Biosciences, Lowers Price Target to $5
benzinga · Aug 14, 2026
CRBU Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for CRBU.
Price Targets
Median: $5.00 (+265.0% from current price)
Source: FMP analyst consensus · as of Aug 25, 2026 · an estimate, not advice
CRBU MoonshotScore
What does this score mean?
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. CRBU scores 15/100 (Grade F): the number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Latest News
BlackRock Inc. Invests $13.76 Million in Caribou Biosciences, Inc. $CRBU
Here's Why You Should Retain IQVIA Stock in Your Portfolio Now
Brokerages Set Caribou Biosciences, Inc. (NASDAQ:CRBU) Price Target at $7.75
B of A Securities Maintains Buy on Caribou Biosciences, Lowers Price Target to $5
Common Questions About CRBU
What does the AI Score mean for CRBU?
CRBU holds an AI Score of 15/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is CRBU a good stock?
Stock Expert AI does not rate CRBU buy, sell or hold. Caribou Biosciences, Inc. carries a MoonshotScore of 15/100 on the five-pillar engine, a research rating against its peers. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What are the key factors to evaluate for CRBU?
Caribou Biosciences, Inc. (CRBU) holds an AI score of 15/100 (low). Analysts target $5.00 (+265%). Not financial advice.
How frequently does CRBU data refresh on this page?
CRBU's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CRBU's recent stock price performance?
Caribou Biosciences, Inc. (CRBU) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CRBU overvalued or undervalued right now?
Caribou Biosciences, Inc. (CRBU) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Analysts target $5.00 (+265%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of CRBU?
Yes, most major brokerages offer fractional shares of Caribou Biosciences, Inc. (CRBU) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track CRBU's earnings and financial reports?
Caribou Biosciences, Inc. (CRBU) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for CRBU earnings announcements.
What should investors new to CRBU understand first?
Caribou Biosciences, Inc. (CRBU) is worth researching across volatility, fundamentals, and industry context. Its current AI score is 15/100. With a market cap of $136M, its size is a factor in volatility characteristics. Start with the Company Overview and MoonshotScore tabs for a structured introduction.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.